Transdiagnostic

4

Review clinical trials related to Transdiagnostic. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Transdiagnostic Sleep and Circadian Treatment for Autistic Adolescents

Sleep and circadian problems are associated with deleterious social, emotional, and cognitive outcomes, yet are modifiable. This prospective study will adapt and optimize an empirically supported behavioral intervention that addresses common sleep and circadian problems of autistic adolescents, who are at increased risk for mental health disorders, using a transdiagnostic approach. The knowledge gained from this study will help to address a critical need for accessible transdiagnostic sleep interventions for autistic adolescents, who experience a broad range of sleep and circadian problems at high rates and often lack access to specialty care treatment.

Participants needed: 12
Trial details
Age: 13-17Biological sex: AllType: InterventionalSponsor: Milton S. Hershey Medical CenterUpdated: Jun 4, 2026
Eligibility criteria

Autistic adolescents diagnosed with Autism Spectrum Disorder (ASD). [+5]

A history of Intelligent Quotient (IQ) < 70. [+2]

Status: Recruiting

Open-Label Psilocybin Study in Transdiagnostic Population

The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing. The investigators will recruit individuals with mood, anxiety, trauma, addictive, or related symptomatology, and who have functional impairment associated with these symptoms. A DSM-5 diagnosis is not required (nor is it an exclusion). The investigators will allow for comorbidity and only exclude based on psychological and physiological safety considerations. Critically, this approach will allow us to assess the tolerability of our interventions in individuals who would typically be excluded from efficacy studies due to various comorbid DSM-5 conditions. The investigators will employ an open-label study where participants will be given one dose of oral psilocybin 25mg. The investigators will also have follow-up visits at 1, 4, and 6 weeks and an optional long-term follow-up at 3, 6, and 12 months.

Participants needed: 50
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Yale UniversityUpdated: Mar 11, 2026Locations: 1
Eligibility criteria

At least one psychiatric symptom causing functional impairment over the past 30... [+12]

Personal history of a primary psychotic disorder (e.g., schizophrenia, delusiona... [+24]

Status: Not yet recruiting

Transdiagnostic Sleep and Circadian Treatment for Autistic Adults

Sleep and circadian problems are associated with deleterious social, emotional, and cognitive outcomes, yet are modifiable. This prospective study will adapt and optimize an empirically supported behavioral intervention that addresses common sleep and circadian problems of autistic adults, who are at increased risk for mental health disorders, using a transdiagnostic approach. The knowledge gained from this study will help to address a critical need for accessible transdiagnostic sleep interventions for autistic adults, who experience a broad range of sleep and circadian problems at high rates and often lack access to specialty care treatment.

Participants needed: 24
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Milton S. Hershey Medical CenterUpdated: Mar 10, 2026
Eligibility criteria

Autistic adults diagnosed with ASD. [+3]

A history of IQ < 70. [+2]

Status: Recruiting

A Mixed Methods Pilot Trial of the STEP Home Workshop to Improve Reintegration and Reduce Suicide Risk for Recently Transitioned Veterans

Risk of Veteran suicide is elevated during the first year of transition from military service to civilian life. Most Veteran suicides occur among Veterans who are not connected to VA healthcare. Suicide prevention and connection to care are therefore critical for recently transitioning Veterans. Transitioning Veterans require services to provide them with suicide prevention education, skills to manage their transition effectively, and support in their access to VA healthcare. Convenient, accessible, palatable, patient-centered care options that are cost-effective, easy to implement nationwide, and target domains known to mitigate suicide risk are needed during this critical transition period. This proposal would bridge this important healthcare gap using STEP-Home-SP, a transdiagnostic, non-stigmatizing, skills-based workshop. STEP-Home-SP will provide Veterans with suicide prevention education, skills to improve transition, support to access VA care, and a platform to decrease social isolation early in their military to civilian transition, thereby reducing suicide risk downstream.

Participants needed: 120
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: VA Office of Research and DevelopmentUpdated: Mar 6, 2026Locations: 1
Eligibility criteria

Recently transitioned Veterans within three years of separation from military se... [+3]

Active psychosis [+5]